Environmental Risk Assessment Framework for Pharmaceuticals
Calculate pharmaceutical environmental risk quotients against ICH M7 regulatory standards
What You Can Do
You can structure complete environmental risk assessments for pharmaceutical submissions by organizing ecotoxicity study data, calculating predicted environmental concentrations and predicted no-effect concentrations across aquatic/terrestrial/sediment compartments, and deriving risk quotients. This determines whether your drug requires Phase I (desktop) or Phase II (comprehensive) assessment, accelerates regulatory timelines, and identifies data gaps before expensive studies are commissioned.
Features
compile and validate OECD guideline study results (acute/chronic fish, daphnia, algae, terrestrial species) against completeness checklists
model environmental concentrations using dose, metabolism, elimination, and wastewater treatment assumptions with transparent assumptions logging
establish predicted no-effect concentrations from study data using species sensitivity distributions, assessment factors, and uncertainty adjustments
calculate PEC/PNEC ratios for each environmental compartment and identify concern thresholds triggering Phase II testing
structure findings against ICH M7 decision trees and regulatory classification (Class 1–5) for ecotoxicity hazards
apply read-across and QSAR predictions to assess environmental hazards of active metabolites with justification frameworks
recommend manufacturing controls, formulation changes, or post-market monitoring to reduce environmental exposure
generate sections ready for IND/CTA/NDA/MAA submissions with standardized tables and narrative structures
Example Output
Example 1: Phase I Risk Characterization Output
| Compartment | Study Data | PEC (μg/L) | PNEC (μg/L) | RQ | Classification |
|---|---|---|---|---|---|
| Aquatic (Fish) | 96h LC50: 45 mg/L | 0.8 | 0.45 | 1.78 | Phase II Required |
| Sediment | 28d Chironomid: 12 mg/kg | 2.1 | 3.2 | 0.66 | Phase I Complete |
Recommendation: Conduct fish early life stage study (OECD 210) to refine PEC calculation and reduce uncertainty factor from 100 to 50.
Example 2: Metabolite Assessment
Active metabolite M7 (20% human AUC exposure): QSAR-predicted fish LC50 = 15 mg/L (Cramer Class II). PEC 0.6 μg/L. RQ = 0.04 (acceptable under Phase I). Read-across to structural analog justified by metabolic stability data.
Example 3: Regulatory Summary for NDA
Environmental Hazard Classification: ICH M7 Class 3 (possible concern). Environmental Risk Quotient: 0.82 (Phase I adequate). Conclusion: No Phase II studies required; post-market monitoring recommended for long-term aquatic effects.
What's Included
- SKILL.md: complete ERA workflow instruction file with ICH M7 decision logic, PEC/PNEC calculation templates, and compliance checklists
- Ecotoxicity Data Compilation Checklist: OECD guideline completeness matrix (fish, daphnia, algae, terrestrial, sediment species)
- PEC/PNEC Calculation Worksheets: step-by-step templates for aquatic, sediment, and terrestrial compartment modeling with assumption documentation
- Risk Quotient Summary Table: standardized format for Phase I/II classification and regulatory decision mapping
- Metabolite Assessment Framework: read-across justification template, QSAR applicability checklist, and hazard uncertainty guidance
Who It's For
- Regulatory Affairs Toxicologists — structure and execute environmental risk assessments for IND/NDA/MAA submissions
- R&D Environmental Safety Scientists — plan Phase I/II testing scope and identify data gaps early in development
- Pharmaceutical Project Managers — estimate regulatory timelines and study costs based on risk classification
- Preclinical CRO Managers — design ecotoxicity study proposals aligned with regulatory requirements
- Quality/Compliance Professionals — document environmental hazard determination for manufacturing approvals and post-market surveillance
Best For
- Environmental hazard characterization for regulatory dossiers (IND, CTA, NDA, MAA)
- Phase I/II risk classification and determination of required study scope
- PEC/PNEC calculation and risk quotient derivation across environmental compartments
- Ecotoxicity dataset synthesis and completeness gap identification
- Metabolite environmental hazard assessment using read-across and QSAR data
You might also like
You can architect end-to-end bioinformatics analysis pipelines by translating your research question into algorithmic approaches, selecting and optimizing appropriate tools and parameters for your dataset, and validating results against biological expectations. This skill guides you through the complete decision tree from raw data to publication-ready interpretation, helping you avoid parameter overfitting, misinterpreted statistical thresholds, and algorithm selection errors that compromise research validity.
by kody-w
You consolidate parallel data streams from preclinical toxicology studies (clinical pathology, histopathology, body weight changes, organ weights, clinical observations, mortality) into coherent regulatory-compliant narratives. This skill synthesizes findings across 6–12 endpoints simultaneously, identifies NOAEL/LOAEL with biological justification, determines safety margins, interprets species-specific or sex-specific signals, and produces Results & Discussion sections that satisfy FDA/EMA reviewers while supporting appropriate dosing decisions for IND-enabling studies.
by kody-wClaude reviews your injection mold, stamping die, or precision tool designs for manufacturability, cost reduction opportunities, and tolerance optimization. You provide CAD specifications, material details, and production volume—Claude identifies specific design modifications, material alternatives, and tolerance adjustments that reduce tooling complexity and unit costs without compromising performance.
by kody-w
You can upload or describe product designs and receive a comprehensive analysis of manufacturing feasibility, cost drivers, and prioritized optimization recommendations. The skill identifies design inefficiencies, material waste opportunities, assembly complexity challenges, and supply chain risks—giving you actionable steps to reduce costs and prevent production delays before they happen.
by kody-w
This skill organizes complex toxicology datasets, clinical adverse events, and mechanistic findings into structured, FDA/EMA-compliant safety narratives. You input raw safety data—adverse event summaries, laboratory results, animal study findings, vital signs—and receive draft safety summaries, detailed safety assessments, and expedited safety reports ready for regulatory submission. It handles IND applications, annual safety updates, clinical development safety overviews, and urgent safety communications with proper MedDRA coding and regulatory formatting.
by kody-w
Upload production cycle time data and Claude will identify process bottlenecks, calculate efficiency metrics, and automatically generate detailed SOPs. You'll get a complete analysis of where time is wasted and structured work instructions that your team can immediately implement to reduce cycle time and improve consistency.
by kody-w
You can take unstructured monitoring visit observations and convert them into formal, audit-ready reports that categorize findings by risk level (Critical, Major, Minor), validate protocol compliance, and generate actionable follow-up items with assigned owners and resolution dates. The skill ensures your documentation meets FDA inspection standards and ICH-GCP requirements while creating clear escalation pathways for high-risk issues.
by kody-w
You can design and execute bioanalytical method validations aligned with FDA Guidance for Industry and ICH guidelines, interpret complex validation data against regulatory acceptance criteria, and systematically troubleshoot analytical failures to identify root causes and corrective actions. This skill accelerates validation timelines by 20–30%, minimizes regulatory rework, and provides structured decision trees for problems that typically require expert consultation.
by kody-w